Evidence map›Paper›PMID 31915546›Full record

ArticleCardiology research and practice2019

Prevalence and Progression of Cognitive Impairment in Atrial Fibrillation Patients after Treatment with Catheter Ablation or Drug Therapy.

Tina S Tischer, Daniel Nitschke, Isabelle Krause, Günther Kundt, Alper Öner, Giuseppe D'Ancona, Erdal Şafak, Hüseyin Ince, Jasmin Ortak, Evren Caglayan

Open access · goldAbstract read
In one paragraph

Article in Cardiology research and practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway.European heart journal. Cardiovascular pharmacotherapy · 2023
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Tina S TischerDepartment of Cardiology, University Hospital, Rostock, Germany.ORCID https://orcid.org/0000-0002-2646-0713
Daniel NitschkeDepartment of Cardiology, University Hospital, Rostock, Germany.
Isabelle KrauseDepartment of Cardiology, University Hospital, Rostock, Germany.
Günther KundtInstitute for Biostatistics and Informatics in Medicine and Ageing Research, University Hospital, Rostock, Germany.
Alper ÖnerDepartment of Cardiology, University Hospital, Rostock, Germany.
Giuseppe D'AnconaDepartment of Cardiology, Vivantes Klinikum im Friedrichshain und Am Urban, Berlin, Germany.
Erdal ŞafakDepartment of Cardiology, Vivantes Klinikum im Friedrichshain und Am Urban, Berlin, Germany.
Hüseyin InceDepartment of Cardiology, University Hospital, Rostock, Germany.
Jasmin OrtakDepartment of Cardiology, Vivantes Klinikum im Friedrichshain und Am Urban, Berlin, Germany.
Evren CaglayanDepartment of Cardiology, University Hospital, Rostock, Germany.
University of Rostock · DEKlinikum im Friedrichshain · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn atrial fibrillation (AF) patients, the effect of catheter ablation or drug therapy on cognition is currently not well investigated. Therefore, we prospectively evaluated AF patients who were either treated 'with drug therapy or underwent catheter ablation for the prevalence and progression of cognitive impairment (CI).

methodsRandomized participants of the CABANA trial (catheter ablation versus antiarrhythmic drug therapy for atrial fibrillation) and the CASTLE-AF (catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation) study were assessed twice within 6 months by Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in our institution.

resultsForty-five patients from both trials were investigated, and twenty-eight patients received catheter ablation, whereas seventeen patients received drug therapy for rhythm or rate control. The mean age of the twenty-one CABANA trial patients (AF group) was 68.8 ± 7.0 years and of the twenty-four CASTLE-AF study patients (AF/HF group) was 66.8 ± 8.1 years, respectively. Mean time from ablation/randomization to the first interview was 16.8 ± 11 months in the AF group and 28.3 ± 18.4 months in the AF/HF group, respectively. All patients investigated were classified as cognitively impaired with mean cutoff scores <24 by MoCA. Overall, we could not detect significant differences in medically treated versus catheter ablation patients within both groups in mean MMSE or MoCA scores between the first and the second interview (

conclusionsPrevalence of cognitive impairment in AF patients with comorbidities is substantial. However, in this preliminary prospective study, no apparent impact of AF pretreatment on the prevalence and course of cognitive impairment could be observed.

Identifiers

PMID31915546
PMCPMC6931025
OpenAlexW2996650713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.